Kiniksa Pharmaceuticals International, plc

US$93.86As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:KNSAHealthcare
Country USA
PE (Fwd) •••
TSR 8Y CAGR 22.34%
Div yield —
ROE 17.59%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.08
PE TTM 70.91
TSR TTM 153.61%
Mkt cap US$7.375B
ROIC 68.29%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$105
11.80%
(66.78%)
Hold 10|0|2|2|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
1.22
1.26
1.38
1.43
11.96%
18.53%
35.13%
27.01%
Revenue$M
398.3
387.9
383.5
383.1
2.72%
(2.70%)
(1.72%)
(3.90%)
Peers (US$7.375B)
Cap (US$)
PE
40.09B
18.72x
2.573B
144.6x
Capital
TTM
5Y
10Y
Leveragex
21.31
0.451
0.369
EBIT/Intx
1.082
0.219
0.204
Own earn%
(12.88)
(62.45)
(46.24)
Sh yield%
39.17
5.62
4.65
Owners
Insiders/Inst%
2.49
89.14
Short interest%
4.31
SBC / revenue%
1.25
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
5
Op margin range%
15–22
$1 testx
—
Incr. ROIC%
15